Understanding a New Factor in HIV Infection
Characterization of a new CXCR4-specific restriction factor
['FUNDING_R21'] · FRED HUTCHINSON CANCER CENTER · NIH-11158991
This research explores how a newly found gene in our cells might control how HIV infects different types of immune cells.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | FRED HUTCHINSON CANCER CENTER (nih funded) |
| Locations | 1 site (SEATTLE, UNITED STATES) |
| Trial ID | NIH-11158991 on ClinicalTrials.gov |
What this research studies
HIV comes in different forms, and while all use CD4+ T cells to infect, they can use different co-receptors, CCR5 or CXCR4. Most new HIV infections start with the CCR5-using type, even though both types can be present later. We've found a new gene, SLC35A2, in CD4+ T cells that seems to block the CXCR4-using HIV type while helping the CCR5-using type. This pattern is similar to how HIV is transmitted. This project will look closely at how SLC35A2 affects these different HIV types in important immune cells found in mucous membranes.
Who could benefit from this research
Good fit: This foundational research does not directly involve patient participation but aims to understand basic biological mechanisms relevant to individuals living with or at risk for HIV.
Not a fit: Patients seeking immediate new treatments or direct clinical intervention would not find direct benefit from this basic science project.
Why it matters
Potential benefit: Understanding this gene could reveal new ways our bodies naturally resist HIV and potentially lead to new strategies for preventing or treating the infection.
How similar studies have performed: While the role of CCR5 and CXCR4 in HIV infection is well-established, the specific gene SLC35A2 as a restriction factor for X4 virus is a novel discovery being explored in this project.
Where this research is happening
SEATTLE, UNITED STATES
- FRED HUTCHINSON CANCER CENTER — SEATTLE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: OVERBAUGH, JULIE M. — FRED HUTCHINSON CANCER CENTER
- Study coordinator: OVERBAUGH, JULIE M.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acquired Immune Deficiency Syndrome Virus, Acquired Immunodeficiency Syndrome Virus